NYXH Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.08% compare to its pairs and should correct upwards.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions...

Stats
Today's Volume	18 896
Average Volume	40 370
Market Cap	241.55M
EPS	$-0.420 ( Q1 \| 2024-03-31 )
Next earnings date	( $-0.450 ) 2024-08-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.39 (Sector) 42.63 (Industry) 78.56
ATR14	$0.0680 (0.97%)

GCTK -4.00%

GMVDW -1.13%

LUCY 6.26%

LUCYW 13.64%

NXGLW 0.00%

NYXH -0.14%

OMIC 0.83%

POCI 5.59%

Correlation (AI algo v.1.1b): Undervalued: 0.08% $7.04 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.15 (neutral)

Short: 0.68 (moderate)

Signal:(41.667) Neutral

Nyxoah S.A. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nyxoah S.A. Correlation - Currency/Commodity

0.14
( neutral )

-0.16
( neutral )

0.00
( neutral )

0.25
( neutral )

0.11
( neutral )

0.08
( neutral )

Nyxoah S.A. Financials

Annual	2023
Revenue:	$4.35M
Gross Profit:	$332 000 (7.64 %)
EPS:	$-1.550

FY	2023
Revenue:	$4.35M
Gross Profit:	$332 000 (7.64 %)
EPS:	$-1.550

FY	2022
Revenue:	$3.08M
Gross Profit:	$1.93M (62.71 %)
EPS:	$-1.210

FY	2021
Revenue:	$852 000
Gross Profit:	$549 000 (64.44 %)
EPS:	$-1.160

Financial Reports:

No articles found.

Nyxoah S.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nyxoah S.A.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.